News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EU Approves Vertex Pharmaceuticals (MA) (VRTX) and Johnson & Johnson (JNJ) Hepatitis C Drug



9/21/2011 7:39:20 AM

Vertex Pharmaceuticals Inc (VRTX.O) and partner Johnson & Johnson (JNJ.N) won European approval for their hepatitis C drug, Vertex said on Tuesday. The pill, which won U.S. approval in May, raked in strong sales of $75 million in the first five weeks it was sold in the country. Known as Incivek in the United States, it will be called Incivo in Europe. J&J has European rights to the product, with Vertex receiving royalties. Vertex holds exclusive rights to the drug in the United States.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES